Inari Medical, Inc. ((NARI)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The PERSEVERE Study, officially titled ‘The PERSEVERE Study,’ is a clinical trial conducted by Inari Medical, Inc. aimed at evaluating the effectiveness of the FlowTriever System compared to the standard of care in treating high-risk pulmonary embolism. This study holds significance as it explores innovative treatment options for a serious condition, potentially improving patient outcomes.
The intervention being tested is the FlowTriever System, a device designed for mechanical thrombectomy in pulmonary embolism cases. It is compared against the standard of care treatment to assess its efficacy and safety.
The study is interventional, with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment, focusing on comparing the two treatment methods.
The study began on December 16, 2024, with its primary completion expected soon after. The last update was submitted on August 11, 2025, indicating ongoing progress in the study’s recruitment and data collection phases.
This clinical study update could influence Inari Medical’s stock performance positively, as successful results may enhance investor confidence and market position. The study’s outcome could also impact the competitive landscape in the medical device industry, particularly in pulmonary embolism treatment.
The PERSEVERE Study is ongoing, with further details available on the ClinicalTrials portal.